Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
OTCMKTS:EDTXF

Spectral Diagnostics Q1 2025 Earnings Results & Report

Spectral Diagnostics logo
$0.73 -0.01 (-1.35%)
As of 11/13/2026 10:03 AM Eastern

Spectral Diagnostics reported Q1 2025 earnings on May 9, 2025. The company reported EPS of -$0.03, while revenue was $400 thousand.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Spectral Diagnostics EPS Results

Actual EPS
-$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 4 quarters

Spectral Diagnostics Revenue Results

Actual Revenue
$400 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Spectral Diagnostics Q1 2025 Earnings FAQ

Spectral Diagnostics (OTCMKTS:EDTXF) reported earnings of -$0.03 per share for Q1 2025. The report was announced on Friday, May 9, 2025.

Spectral Diagnostics reported revenue of $400 thousand for Q1 2025.

Spectral Diagnostics Earnings Headlines

Spectral Medical Inc EDTXF
September 23, 2026  |  morningstar.comM
Spectral Medical Announces U.S. FDA Filing of PMA Application for PMX
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317411/0/en/spectral-medical-announces-u-s-fda-filing-of-pma-application-for-pmx.html
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
November 14 at 1:00 AM  |  Behind the Markets (Ad)
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3309336/0/en/spectral-medical-inc-announces-results-of-annual-and-special-meeting-of-shareholders.html
Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris Trial
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306639/0/en/spectral-medical-and-vantive-announce-topline-12-month-follow-up-results-from-spectral-s-tigris-trial.html
Spectral Medical Announces PMA Submission to U.S. FDA for PMX
May 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/29/3303492/0/en/spectral-medical-announces-pma-submission-to-u-s-fda-for-pmx.html
See More Spectral Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email.

About Spectral Diagnostics

Spectral Diagnostics, now known as Spectral Medical Inc., is a Toronto-based medical technology company focused on the diagnosis and treatment of sepsis and septic shock. Its work centers on detecting endotoxin, a bacterial toxin associated with severe infection and organ dysfunction.

The company’s Endotoxin Activity Assay (EAA) is a blood test designed to help clinicians identify elevated endotoxin activity in critically ill patients. Spectral also develops polymyxin B hemoperfusion, an extracorporeal therapy intended to remove endotoxin from the blood; the therapy has been studied for use in patients with septic shock.

Formerly named Spectral Diagnostics (OTCMKTS:EDTXF), the company has focused on sepsis-related products for decades. Its activities include developing and commercializing the EAA and advancing its endotoxin-removal therapy through clinical research.

View Spectral Diagnostics Profile
Earnings Tools